InsidersTradesSigma
Total declarations
Companies
▲ Purchases (21 ops.)
▼ Sales (14 ops.)
Insider track record
OtherDisclosed buys
21
Disclosed sells
14
T+90 hit rate
0%
T+90 mean return
-10.5%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Bienaime Jean Jacques. Insider active across 5 companies, notably Biomarin Pharmaceutical INC. In total, 80 filings have been logged. Split: 21 buys · 14 sells. Total volume traded: €3.1m. History available since 30 April 2021. The latest transaction was filed on 17 August 2026 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Bienaime Jean Jacques
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations80 total
1,000 shares@ US$10.27Common StockSEC:0001221590-26-000025:0
Canonical exit: 15 Nov 2026 (T+90)
1,100 shares@ US$245.850.0017% mcap38.8% of flowOrdinary SharesSEC:0001610717-26-000360:0
Canonical exit: 12 Nov 2026 (T+90)
900 shares@ US$246.910.0014% mcap31.8% of flowOrdinary SharesSEC:0001610717-26-000360:1
Canonical exit: 12 Nov 2026 (T+90)
1,000 shares@ US$10.610.0049% mcap24.0% of flowCommon StockSEC:0001221590-26-000023:0
Canonical exit: 13 Oct 2026 (T+90)
1,000 sharesCommon StockSEC:0001221590-26-000021:0
Canonical exit: 13 Sept 2026 (T+90)
1,642 sharesCommon StockSEC:0001221590-26-000017:0
500 shares@ US$19.440.0004% mcap1.5% of flowCommon StockSEC:0001221590-26-000015:0
10,000 shares@ US$19.410.0071% mcap29.1% of flowCommon StockSEC:0001221590-26-000015:1
6,000 shares@ US$19.480.0043% mcap17.5% of flowCommon StockSEC:0001221590-26-000015:2
Canonical exit: 3 Sept 2026 (T+90)
3,500 shares@ US$19.460.0025% mcap10.2% of flowCommon StockSEC:0001221590-26-000015:3
Canonical exit: 3 Sept 2026 (T+90)
1,000 shares@ US$19.270.0007% mcap2.9% of flowCommon StockSEC:0001221590-26-000015:4
Canonical exit: 3 Sept 2026 (T+90)
7,142 shares0Common StockSEC:0001221590-26-000013:0
200 shares@ US$223.7621.7% of flowOrdinary SharesSEC:0001610717-26-000177:0
Canonical exit: 27 Aug 2026 (T+90)
200 shares@ US$222.3021.5% of flowOrdinary SharesSEC:0001610717-26-000177:1
Canonical exit: 27 Aug 2026 (T+90)
100 shares@ US$223.5010.8% of flowOrdinary SharesSEC:0001610717-26-000177:2
Canonical exit: 27 Aug 2026 (T+90)
15,000 shares@ US$84.530.0057% mcap50.0% of flowCommon StockSEC:0001221590-26-000011:0
13,059 shares@ US$97.100.0057% mcap50.0% of flowCommon StockSEC:0001221590-26-000011:1
200 shares@ US$239.367523.1% of flowOrdinary SharesSEC:0001610717-26-000161:1
Canonical exit: 24 Aug 2026 (T+90)
200 shares@ US$236.23522.8% of flowOrdinary SharesSEC:0001610717-26-000161:0
Canonical exit: 24 Aug 2026 (T+90)
1,000 shares@ US$11.700.0051% mcap100.0% of flowCommon StockSEC:0001221590-26-000005:0
Canonical exit: 14 Jul 2026 (T+90)
1,000 shares@ US$22.123.0% of flowCommon StockSEC:0001221590-26-000003:0
Canonical exit: 8 Jun 2026 (T+90)
2,000 shares@ US$11.2166.3% of flowCommon StockSEC:0001221590-26-000002:0
Canonical exit: 7 Jun 2026 (T+90)
2,518 shares0Common StockSEC:0001628280-25-031009:0
5,250 shares0Common StockSEC:0001415889-25-015971:0
5,000 shares@ US$9.386.7% of flowCommon StockSEC:0001415889-25-015478:0
Canonical exit: 1 Sept 2025 (T+90)
25 of 80 declarations
About Bienaime Jean Jacques
Jean Jacques Bienaime is a director at Biomarin Pharmaceutical INC, Immunome Inc., INCYTE CORP, Keros Therapeutics, Inc. and Ascendis Pharma A/S. He has filed 76 forms in total, and over the sampled filings period from 2021-05-03 to 2026-06-17, the reported amounts are EUR 666429 of purchases and EUR 1971653 of sales, with option exercise as the most frequent transaction type.
